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Abstract
VCP/p97 regulates numerous cellular functions by mediating protein degradation through its segregase activity. Its key role
in governing protein homoeostasis has made VCP/p97 an appealing anticancer drug target. Here, we provide evidence that
VCP/p97 acts as a regulator of cellular metabolism. We found that VCP/p97 was tied to multiple metabolic processes on the
gene expression level in a diverse range of cancer cell lines and in patient-derived multiple myeloma cells. Cellular VCP/p97
dependency to maintain proteostasis was increased under conditions of glucose and glutamine limitation in a range of cancer
cell lines from different tissues. Moreover, glutamine depletion led to increased VCP/p97 expression, whereas VCP/p97
inhibition perturbed metabolic processes and intracellular amino acid turnover. GCN2, an amino acid-sensing kinase,
attenuated stress signalling and cell death triggered by VCP/p97 inhibition and nutrient shortages and modulated ERK
activation, autophagy, and glycolytic metabolite turnover. Together, our data point to an interconnected role of VCP/p97 and
GCN2 in maintaining cancer cell metabolic and protein homoeostasis.
Introduction
Cancer cells have a heightened dependency on the mechan-
isms of protein degradation to maintain protein homoeostasis
(proteostasis) [1]. Therefore, drugs that disrupt protein
breakdown and trigger proteotoxic stress have considerable
potential for anticancer therapy [2, 3]. This proposition is
supported by the clinical success of inhibitors of the protea-
some, the main effector of intracellular protein degradation, in
multiple myeloma (MM) [4]. VCP/p97 is an AAA+ (ATPase
associated with diverse cellular activities) ATPase that is
conserved across diverse species, is essential for life in bud-
ding yeast and mice, and is abundantly expressed [5–8]. VCP/
p97 exerts a segregase activity that uses energy derived from
ATP hydrolysis to remodel client proteins, and engages in
multiple cellu lar processes that include chromosome segre-
gation, DNA repair, endoplasmic reticulum (ER) and Golgi
formation, and activation of NF-κB [9–16]. Its role is best
understood in the context of ER-associated degradation
(ERAD), where VCP/p97 mediates the delivery of ubiquiti-
nated misfolded ER proteins to the proteasome [17–19].
However, VCP/p97 has also been linked to proteasome-
independent handling of protein aggregates and autophagy
* Holger W. Auner
holger.auner04@imperial.ac.uk
1 Cancer Cell Protein Metabolism Group, Centre for Haematology,
Department of Medicine, Imperial College London, London, UK
2 Division of Cancer, Department of Surgery and Cancer, Imperial
College London, Hammersmith Hospital, London, UK
3 Centre for Haematology, Department of Medicine, Imperial
College London, London, UK
4 Division of Molecular Pathfology, Institute of Cancer Research,
Sutton, UK
5 INSERM U1242, Chemistry, Oncogenesis, Stress, Signaling,
Université de Rennes 1, Rennes, France
6 Centre de Lutte Contre le Cancer Eugène Marquis Rennes,
Rennes, France
Supplementary information The online version of this article (https://
doi.org/10.1038/s41388-018-0651-z) contains supplementary material,















[20–23]. Moreover, VCP/p97 has been implicated in protea-
some recovery after proteasome inhibition [24–26]. This
broad involvement of VCP/p97 in regulating protein homo-
eostasis suggests that VCP inhibitors could overcome ther-
apeutic limitations of proteasome inhibitors [1, 27]. Indeed,
VCP/p97 inhibitors trigger fatal ER stress in cancer cells
in vitro and in vivo [22, 28–30]. Increased expression levels
of VCP/p97 have been observed in multiple cancers and may
explain the preferential toxicity of VCP/p97 inhibition in
cancerous compared to non-malignant cell lines [22, 31–33].
Recently, anticancer effects of the alcohol-abuse drug dis-
ulfiram have been linked to VCP/p97 and its adaptor NPL4
[34]. Thus, VCP/p97 and its adaptors are promising ther-
apeutic targets in oncology [29, 35, 36]. However, the func-
tional links between VCP/p97 and cellular metabolism, and
the effects of nutrient availability on cancer cells targeted by
VCP/p97 inhibition, remain to be established. Additional
therapeutic relevance of such interactions is highlighted by the
observation that VCP/p97 promotes degradation of glutamine
synthetase (GS) downstream of CRBN, the target of so-called
immunomodulatory drugs [37].
Cancer cells adapt their metabolic networks to recon-
cile the need for increased anabolic biomass synthesis and
catabolic energy production with suboptimal nutrient
supplies [38–40]. The reprogramming of cellular meta-
bolism can confer survival advantages to tumour cells but
also offers therapeutic opportunities [41]. Glutamine and
glucose are two principal nutrients that support cell
growth and survival, and the high demand of cancer cells
for both molecules has been known for many decades
[42–44]. Moreover, limited availability of glutamine and
glucose in tumours may have a detrimental effect on
therapeutic responses [45–52]. The amino acid-sensing
kinase GCN2 (EIF2AK4) provides a direct link between
nutrient availability and protein homoeostasis [53]. Upon
activation by uncharged tRNAs or ribosome stalling,
GCN2 phosphorylates its only known target, eIF2α,
resulting in attenuation of overall protein synthesis [54–
56]. GCN2 also regulates amino acid homoeostasis
through sestrin2-mediated repression of mTORC1 and
induction of autophagy [57–60]. GCN2 supports cancer
cell survival under conditions of amino acid or glucose
deprivation but may also promote cell death upon pro-
longed nutrient depletion [61–63].
Here, we present evidence that VCP/p97 acts as a
central regulator of cellular metabolism. Furthermore, we
uncover a role for GCN2 to promote cell viability during
nutrient deprivation and VCP/p97 inhibitor-induced
proteotoxic stress. Together, our data point to a
pivotal and interconnected role of VCP/p97 and GCN2
in maintaining cancer cell metabolic and protein
homoeostasis.
Results
Cancer cell dependency on VCP/p97 is linked to
metabolic processes and nutrient availability
To investigate whether VCP/p97 is linked to cancer cell
metabolism, we first interrogated the Cancer Cell Line
Encyclopedia (CCLE) [64]. We found that VCP/p97
mRNA expression across 917 CCLE cancer cell lines sig-
nificantly correlated with 162 Kyoto Encyclopedia of Genes
and Genomes (KEGG) terms. As expected, these included
several processes linked to protein folding, sorting, and
degradation such as ‘ubiquitin-mediated proteolysis’, ‘pro-
tein processing in endoplasmic reticulum’, and ‘protea-
some’. When ranked by significance levels, the top three
KEGG terms linked to VCP/p97 expression were ‘meta-
bolic pathways’, ‘pathways in cancer’, and ‘PI3K-Akt sig-
nalling pathway’ (Fig. 1a and Supplementary Table 2).
VCP/p97 expression was also significantly correlated with
22 cancer-specific pathways linked to both solid and hae-
matopoietic malignancies, and with 14 metabolic pathways
including ‘glycolysis/gluconeogenesis’, ‘carbon metabo-
lism’, and ‘biosynthesis of amino acids’. Moreover, VCP/
p97 expression correlated with several processes that are
linked to cellular metabolism and are frequently deregulated
in cancer, such as ‘mTOR signalling pathway’ and ‘MAPK
signalling pathway’ (Supplementary Table 2). Next, we
tested if VCP/p97 expression is linked to metabolic path-
ways in purified bone marrow tumour cells of 261 patients
with MM [65]. Out of 76 KEGG terms that correlated
significantly with VCP/p97 expression, which contained
‘ubiquitin-mediated proteolysis’, ‘protein processing in
endoplasmic reticulum’, and ‘proteasome’, 32 terms were
metabolic pathways that included central processes such as
‘citrate cycle (TCA cycle)’ and ‘carbon metabolism’ (Sup-
plementary Table 3). As with the CCLE data, the top co-
regulated KEGG pathway was ‘metabolic pathways’ (Fig.
1b). Taken together, these data demonstrate that VCP/p97
is, at the level of gene expression, tied to multiple metabolic
pathways, including several that are directly linked to the
processing of nutrients, in a diverse range of cancers.
We then set out to investigate the link between VCP/p97-
guarded protein homoeostasis and nutrient availability in
cultured cells. First, we knocked down VCP/p97 in A549
lung adenocarcinoma cells using stable inducible small
hairpin RNAs (shRNAs) and quantified mRNA levels of
BIP and CHOP as markers of the unfolded protein response
(UPR) and integrated stress response (ISR), respectively,
after glutamine or glucose depletion [66–68]. We observed
that shRNA-mediated VCP/p97 mRNA reduction by
approximately 60% did not significantly alter CHOP or BIP
transcript levels in cells maintained in complete medium
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(Fig. 1c), indicating that the remaining VCP/p97 activity
was sufficient to maintain proteostasis under conditions of
optimal nutrient supply. Depletion of glucose or glutamine
in control (non-targeting shRNA) cells resulted in higher
levels of both CHOP and BIP mRNAs, indicating that both
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Compared to control cells, CHOP and BIP mRNAs were
significantly more upregulated in VCP/p97 knockdown
cells exposed to low glucose conditions, but not in VCP/
p97 knockdown cells depleted of glutamine (Fig. 1c).
Considering that an inducible knockdown reduces mRNA
and protein levels gradually and incompletely, potentially
allowing cells to adapt to a reduction of VCP/p97 activity,
we turned to CB5083, a selective inhibitor of the VCP/p97
ATPase that has been undergoing early preclinical and
clinical testing in solid and haematopoietic malignancies
(NCT02243917, NCT02223598) [29, 35]. In parental A549
cells, glucose restriction induced BIP (13-fold) and CHOP
mRNAs (44-fold) considerably more than glutamine
depletion (2.5-fold and 5-fold, respectively). We also
observed CB5083-induced upregulation of BIP (16-fold)
and CHOP (55-fold) mRNAs in cells grown in complete
medium. This was increased further by glucose and gluta-
mine depletion, although the additional CHOP induction in
glutamine-depleted cells was not statistically significant
(Fig. 1d). Consistent with the increased expression of
CHOP and BIP mRNAs, nutrient depletion also increased
the levels of CB5083-induced cell death in A549 cells (Fig.
1e). Glutamine depletion and, to some extent, glucose
limitation, also resulted in higher levels of CB5083-induced
cell death in PC3 prostate cancer, MCF-7 breast cancer, and
Saos-2 osteosarcoma cell (Supplementary Figure 1).
Moreover, glucose and glutamine depletion significantly
increased CB5083-induced caspase activation in A549 cells
(Supplementary Figure 2). This effect of nutrient depletion
on caspase activation was also observed in other cell types,
including DU145 and PC3 prostate cancer and MCF-7
breast cancer cells, albeit at different levels, and with glu-
tamine depletion generally having a more pronounced effect
than glucose limitation (Supplementary Figure 2). Caspase
inhibition with the pan-caspase inhibitor z-VAD-fmk
reduced cell death caused by CB5083 treatment and nutri-
ent depletion (Supplementary Figure 3). Thus, depletion of
glucose and glutamine increases proteotoxic stress that is at
least partly ER-related and triggers partly caspase-
dependent apoptotic death, upon genetic or pharmacologi-
cal VCP/p97 depletion.
We then tested whether suboptimal nutrient availability
would alter VCP/p97 expression and observed that gluta-
mine depletion upregulated VCP/p97 mRNA in A549,
DU145, and A172 (glioblastoma) cells (Fig. 1f). However,
we did not detect an unequivocal increase in VCP/p97
protein levels by immunoblotting (Supplementary Figure
4), possibly because of high baseline expression levels and
limited sensitivity of the approach. Glucose restriction did
not appear to trigger VCP/p97 mRNA upregulation (Fig.
1f). Taken together, the results indicate increased cellular
VCP/p97 dependency to maintain proteostasis when nutri-
ent supplies are suboptimal. The data also suggest that
glutamine depletion triggers compensatory mechanisms that
appear to be more effective in attenuating stress than those
induced by glucose depletion. Finally, we also determined
that VCP/p97 mRNA or protein expression did not correlate
with cellular sensitivity to CB5083 (Supplementary Figure
5), a finding compatible with our previous observations in a
panel of cancer cell lines largely composed of MM cells and
treated with the VCP/p97 inhibitors DBeQ and NMS-873
[30]. However, the degree to which BIP and CHOP mRNAs
are upregulated in A549 cells in response to CB5083 is
concentration dependent, as is the degree of cell death in
response to CB5083 in a range of cancer cells (Supple-
mentary Figure 6). Thus, VCP/p97 inhibition kills cancer
cells in a dose-responsive manner.
VCP/p97 inhibition perturbs key metabolic
pathways
To further investigate how VCP/p97 regulates cellular
metabolism, we used gas chromatography–mass spectro-
metry (GC–MS) to quantify intracellular metabolites in cells
treated with CB5083 under different conditions of nutrient
availability. As expected, glucose depletion alone resulted
in significant decreases in glycolytic metabolites, and in
decreased levels of some nucleotide metabolites and amino
acids (Supplementary Figure 7). Glutamine depletion also
Fig. 1 VCP/p97-governed proteostasis is tied to metabolic pathways
and nutrient availability. a Network graph of leading-edge enriched
genes from the top three most highly enriched KEGG pathways. Edge
weight and size indicate strength of correlation between genes/nodes.
Nodes are coloured by the pathways each gene contributes to. b GSEA
plots of the KEGG term Metabolic Pathways, with genes ranked by
correlation with VCP/p97 expression, in the Cancer Cell Line Ency-
clopedia (CCLE) and in patient-derived tumour cells in the Myeloma
IX study. The correlation value of individual genes is indicated by
black bars (left axis) and running enrichment score is highlighted by
red line (right axis). NES normalised enrichment score. c Relative
mRNA levels of the indicated genes in A549 cells stably expressing
non-targeting control (NTC) or one of two IPTG-inducible VCP/
p97 shRNAs after 48 h of IPTG treatment in complete medium (25
mM glucose, 2 mM glutamine), followed by 24 h maintenance in
complete, low glucose (1 mM glucose, 2 mM glutamine) or no glu-
tamine (25 mM glucose, 0 mM glutamine) medium supplemented with
500 μM IPTG. Data shown are mean and SEM, n= 3 (two-way
ANOVA with Tukey’s multiple comparisons test). d Relative mRNA
levels of the indicated genes in A549 cells grown under different
conditions of nutrient availability and treated with CB5083 (1 μM) as
indicated for 16 h. Data shown are mean and SEM, n= 3 (two-way
ANOVA with Tukey’s multiple comparisons test). e Proportion of
non-viable A549 cells as determined by Annexin V and 7-AAD
staining after treatment with CB5083 under the indicated conditions of
nutrient availability for 48 h. Data shown are mean and SEM, n= 3
(two-way ANOVA with Sidak’s multiple comparisons test). f VCP/
p97 mRNA expression in the indicated cell lines grown in complete,
low glucose or no glutamine medium for 16 h (A549), 24 h (DU145),
or 48 h (A172). Data shown are mean and SEM, n= 3 (Mann–
Whitney test)
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affected glycolytic and nucleotide metabolites, although to a
lesser extent than glucose limitation, and was linked to
significant decreases in levels of TCA cycle intermediates
and of some amino acids, including glutamine and gluta-
mate. In contrast, inhibition of VCP/p97 in A549 cells
grown in complete medium was predominantly linked to
significant increases in the levels of most amino acids, with
tyrosine and glutamine being the most affected (Fig. 2a, b).
CB5083 treatment also triggered increases of TCA cycle,
glycolytic, and nucleotide metabolites. Somewhat intrigu-
ingly, when considering the increased toxicity of VCP/p97
inhibition in low glucose conditions, VCP/p97 inhibition
largely countered the effects of glucose limitation on
metabolites. Compared to low glucose conditions alone,
CB5083 treatment significantly increased the intracellular
levels of most nucleotide metabolites, glycolytic inter-
mediates, TCA cycle components, and amino acids (Fig. 2a,
b). In sharp contrast, the effects of VCP/p97 inhibition in
glutamine-depleted cells were small or insignificant. These
results provide further evidence for an important role of
VCP/p97 in regulating intracellular metabolism and support
the notion that mechanisms to compensate for the metabolic
effects of pharmacological VCP/p97 inhibition are activated
under glutamine-limiting conditions.

























































































Fig. 2 Metabolite responses to VCP/p97 inhibition. A549 cells were
grown in complete (25 mM glucose, 2 mM glutamine), low glucose (1
mM glucose, 2 mM glutamine), or no glutamine (25 mM glucose, 0
mM glutamine) medium for 16 h followed by intracellular metabolite
extraction and gas chromatography-mass spectrometry. Data show the
effects of CB5083 treatment (1 μM) for 16 h. a Volcano plots indi-
cating metabolites with significant changes (coloured). The horizontal
dashed line represents a multiple testing-adjusted p-value of 0.05, and
the vertical dashed lines represent log2 fold changes of 0.67 and 1.5,
respectively. b Bar graphs show the effect of treatment with CB5083
on individual metabolites (fold change of treatment to control for each
of the three media compositions). Comparisons with significant effects
(two-way ANOVA, n= 4 per experimental condition) are outlined in
red
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GCN2 attenuates stress signalling triggered by VCP/
p97 inhibition and glutamine deprivation
We have previously shown that VCP/p97 inhibition triggers
time- and concentration-dependent phosphorylation of
GCN2 on Thr889, suggesting its activation [30]. Observa-
tions that GCN2 may promote tumour growth or induce
apoptosis under conditions of metabolic stress and nutrient
deprivation led us to investigate the role of GCN2 in cells
challenged by VCP/p97 inhibition [61, 63, 68–70]. We first
determined the effect of GCN2 depletion by stable shRNA-
mediated knockdown (Fig. 3a) on cell viability. VCP/p97
inhibition, nutrient depletion, or both together consistently
triggered higher levels of death of GCN2-depleted cells than
of control cells. However, the differences were only statis-
tically significant when cells were stressed by both CB5083
treatment and nutrient depletion (Fig. 3b). Under these
conditions, cell death rates were approximately twice as
high in shGCN2 cells compared to control cells. GCN2-
depleted cells also expressed higher levels of CHOP mRNA
than control cells in low glucose medium, or when they
were exposed to CB5083 under glucose- or glutamine-
depleted conditions (Fig. 3c). BIP mRNA levels showed a
similar trend as CHOP levels but the differences were small
and not statistically significant. These observations suggest
that, under the stress conditions tested, GCN2 promotes
survival and attenuates stress signalling linked to CHOP
expression but may not be directly linked to protein folding
mechanisms in the ER. We also found higher levels of
CB5083-induced caspase activation in GCN2-depleted
A549 cells in glutamine-limiting conditions (Supplemen-
tary Figure 8). The findings also suggest that the survival-
promoting role of GCN2 is most relevant under complex
stress conditions of combined VCP/p97 inhibition and
nutrient depletion. In line with this notion, we found that
GCN2 mRNA was upregulated by CB5083, and that this
increase in mRNA levels was further accentuated by glu-
tamine depletion, although the changes were numerically
small and did not reach statistical significance (Supple-
mentary Figure 9).
GCN2 has been reported to mediate cell death under
conditions of prolonged glucose restriction, and this pro-
apoptotic function was linked to activation of ERK2
upstream of GCN2 [63]. However, we observed that glu-
cose depletion reduced ERK1/2 phosphorylation rapidly
and persistently (Fig. 3d). Glutamine depletion caused a
transient reduction in ERK phosphorylation, and treatment
with CB5083 did not have a discernible effect on ERK
phosphorylation, irrespective of nutrient availability. While
GCN2 depletion had no distinct effect on ERK phosphor-
ylation in cells grown in complete or low glucose medium,
we observed a trend towards higher levels of ERK phos-
phorylation in GCN2-depleted cells that were deprived of
glutamine, irrespective of whether they were, or were not,
treated with CB5083. To determine how ERK regulates cell
fate under these stress conditions, we quantified cell viabi-
lity after ERK inhibition in GCN2 competent and depleted
cells grown without glutamine. First, providing further
evidence for a pro-survival role of GCN2 under stress
conditions, we observed significantly higher levels of cell
death in GCN2-depleted cells treated with CB5083 com-
pared to control cells (Fig. 3e and Supplementary Figure
10a). ERK inhibition with two small molecule inhibitors
was generally linked to a numeric increase in cell death,
although the effects were not statistically significant (Fig. 3e
and Supplementary Figure 10b). Thus, we did not find that a
pro-apoptotic ERK signalling pathway that involves GCN2
was active in our cellular model system and under the stress
conditions tested. In contrast, GCN2, and to a small extent
ERK, promoted survival.
Autophagy promotes cell survival under complex
stress conditions
Macroautophagy, thereafter referred to as autophagy, is a
highly conserved intracellular pathway whose primary
function is to sustain cellular metabolism during nutrient
starvation. Autophagy has been linked to VCP/p97 inhibi-
tion experimentally, albeit with conflicting findings as to
whether VCP/p97 inhibition suppresses or induces autop-
hagy [22, 29]. Autophagy has also been reported to be
induced downstream of GCN2 [57–59, 71, 72]. We found
that VCP/p97 expression is linked to autophagic processes
across the CCLE (Fig. 4a). We also observed that ATG7
mRNA levels were significantly higher in GCN2-depleted
cells grown in low glucose and no glutamine medium when
treated with CB5083, while ATG5 mRNA was significantly
upregulated only in GCN2-depleted cells grown in no
glutamine medium and treated with CB5083 (Fig. 4b). We
also observed that, as expected, both glutamine and glucose
depletion induced autophagy when assessed by immuno-
blotting for LC3BII, at the 36 h time point (Fig. 4c). VCP/
p97 inhibition with CB5083 also appeared to induce
autophagy in cells maintained in complete and nutrient-
depleted medium, based on higher LC3BII and lower p62
levels. While GCN2 depletion did not have a detectable
impact on LC3B or p62 levels in most conditions tested, we
observed a possible trend to higher LC3BII levels in
shGCN2 compared to shNTC cells that were glutamine-
depleted, irrespective of whether they were or were not
treated with CB5083. GCN2 depletion was also linked to
lower levels of p62 in CB5083-treated cells compared to
control cells. Thus, while LC3BII levels were affected by
nutrient depletion or VCP/p97 inhibition, p62 levels and
key autophagy mRNAs were only affected when cells
experienced a combined metabolic challenge of GCN2
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depletion, VCP/p97 inhibition, and nutrient limitation, in
particular glutamine depletion. We then set out to test if the
effects of autophagy were cytoprotective by blocking
autophagy for 16 h with bafilomycin A1 after an 8-h
CB5083 pre-treatment of glutamine depleted cells. We
confirmed the effects of CB5083 on LC3B and p62 levels at
the single time point used in this experiment, and that these
effects were enhanced in GCN2-depleted cells (Fig. 4d).
Moreover, we found that treatment with bafilomycin A1
resulted in a stronger LC3BII immunoblot signal, which is
consistent with an increased autophagic flux in the CB5083-
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Fig. 3 GCN2 modulates proteotoxic stress and ERK signalling in
response to VCP/p97 inhibition. a Immunoblot for GCN2 and β-
tubulin on extracts from untransduced A549 cells and A549 cells
stably expressing targeting (shGCN2) or non-targeting (shNTC)
shRNA. b-e A549 cells stably expressing non-targeting control
(shNTC) or one of two shRNAs targeting GCN2 (shGCN2) were
grown in complete (25 mM glucose, 2 mM L-glutamine), low glucose
(1 mM glucose, 2 mM glutamine), or no glutamine (25 mM glucose, 0
mM glutamine) medium. CB5083 was used at 1 μM. b Proportion of
non-viable A549 cells as determined by Annexin V-FITC and 7-AAD
staining after 48 h of experimental treatment. Data shown are mean
and SEM, n= 3 (two-way ANOVA with Tukey’s multiple compar-
isons test). c mRNA levels relative to shNTC expressing cells grown in
complete medium after 16 h of experimental treatment. Data shown are
mean and SEM, n= 3 (two-way ANOVA with Tukey’s multiple
comparisons test). d Immunoblot analyses on whole-cell extracts from
A549 cells (three independent experiments) stably expressing shNTC
or shGCN2(1). Bar graphs show relative phosphorylated ERK1/2
immunoblot band intensities (mean and SEM) compared to control
cells. e Proportion of non-viable A549 cells as determined by Annexin
V and 7-AAD staining after 24 h of experimental treatment with
AZD6244, U0126, and CB5083 for 24 h. Mean and SEM of n= 3
experiments is shown (two-way ANOVA and Tukey’s multiple
comparisons for effects of AZD6244 and U0126 compared to vehicle-
treated or CB5083-treated cells; two-way ANOVA and Bonferroni’s
multiple comparisons test for effects of shGCN2 compared to shNTC
under the same experimental conditions (grey asterisks); exact p values
for all comparisons are shown in Supplementary Figure 10)
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pronounced in the GCN2-depleted cells, in keeping with
higher levels of autophagy. When we determined cell via-
bility, we found that bafilomycin A1 significantly increased
cell death in CB5083-treated shNTC and shGCN2 cells, but
did not have a significant effect on viability in cells not
exposed to CB5083 (Fig. 4e). Taken together, the data
indicate that autophagy is induced to limit the deleterious
effects of combined glutamine depletion and VCP/p97
inhibition, and that this effect is particularly noticeable in
GCN2-depleted cells. Thus, both autophagy and GCN2
play a role in maintaining cell survival under these stress
conditions.
GCN2 attenuates the depletion of glycolytic
metabolites under low glucose conditions
Our findings that GCN2 promotes viability under conditions
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Fig. 4 GCN2 attenuates autophagy in response to metabolic and pro-
teotoxic stress. A549 cells stably expressing non-targeting control
(shNTC) or one of two shRNAs targeting GCN2 (shGCN2) were
grown in complete (25mM glucose, 2 mM L-glutamine), low glucose
(1 mM glucose, 2 mM glutamine), or no glutamine (25mM glucose, 0
mM glutamine) medium. CB5083 was used at 1 μM. a GSEA plot of
KEGG autophagy pathway with genes ranked by correlation with VCP/
p97 expression. The correlation value of individual genes is indicated
by black bars (left axis) and running enrichment score is highlighted by
red line (right axis). NES normalised enrichment score. b mRNA levels
relative to shNTC expressing cells grown in complete medium after 16
h of experimental treatment. Data shown are mean and SEM, n= 3
(two-way ANOVA with Tukey’s multiple comparisons test). c
Immunoblot analyses on whole-cell extracts from A549 cells (three
independent experiments) stably expressing shNTC or shGCN2(1). Bar
graphs show relative LC3BII and p62 immunoblot band intensities,
compared to control cells (mean and SEM). d Immunoblot analyses on
whole-cell extracts from A549 cells treated with CB5083 (1 μM) for 24
h and bafilomycin A1 (100 nM) for 16 h. e Propoof non-viable A549
cells treated with CB5083 (1 μM) for 48 h and bafilomycin A1 (100
nM) for 40 h. Data shown are mean and SEM, n= 3 (two-way
ANOVA and Tukey’s multiple comparisons test)
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known roles of GCN2 in regulating protein synthesis via
eIF2α and autophagy in response to amino acid shortages,
prompted us to investigate the effect of GCN2 depletion on
intracellular metabolites. Somewhat surprisingly, stable
GCN2 knockdown was linked to very limited effects on
metabolites in cells grown in complete or glutamine-
depleted medium (Fig. 5a). In cells grown under low glu-
cose conditions, GCN2 depletion was linked to significantly
increased levels of some nucleotide metabolites, glucose-6-
phosphate, and lactate. We also observed significantly
increased alanine levels in GCN2-depleted cells, in keeping
with higher lactate levels. Significant effects of GCN2
depletion in cells treated with CB5083 were limited to low
glucose conditions, under which some nucleotide metabo-
lites, alanine, and lactate accumulated in GCN2-depleted
cells. Thus, GCN2 activity attenuated depletion of glyco-
lytic metabolites under low glucose conditions but had a
limited overall role in regulating intracellular metabolites.
GCN2 is not required to attenuate protein synthesis
under conditions of proteotoxic or nutrient stress
The translation initiation factor eIF2α is the only known
direct GCN2 target, but there are several eIF2α kinases that
are thought to respond to different stress situations [53].
Somewhat surprisingly, we observed that glucose depletion,
which is predicted to result in protein misfolding and thus
trigger eIF2α phosphorylation by PERK, substantially
reduced the levels of eIF2αSer51 phosphorylation at early
(6 h) and late (36 h) time points in control cells. However,
eIF2αSer51 phosphorylation was largely maintained in
GCN2-depleted cells at the 6 h time point (Fig. 5b). Glu-
tamine depletion also resulted in lower levels of eIF2α
phosphorylation, but the reduction in eIF2αSer51 phosphor-
ylation in control cells was less pronounced than in glucose-
depleted cells at the early and late time point. Intriguingly,
the level of eIF2αSer51 phosphorylation was higher in
GCN2-depleted cells than in control cells at the 36 h time
point. In contrast to nutrient depletion, VCP/p97 inhibition
in control cells grown in complete medium triggered the
predicted [29, 30] increase in eIF2αSer51 phosphorylation,
particularly at the 36 h time point (Fig. 5b). However, this
was not observed in GCN2-depleted cells. The effects of
VCP/p97 inhibition on eIF2αSer51 phosphorylation under
glucose or glutamine-depleted conditions were very similar
to the effects of nutrient depletion alone. Thus, eIF2αSer51
phosphorylation that was triggered by VCP/p97 inhibition
depended on GCN2, but only when glucose and glutamine
were abundant. In contrast, unidentified mechanisms partly
maintain eIF2αSer51 phosphorylation early after glucose
deprivation, and increase eIF2αSer51 phosphorylation late
after glutamine withdrawal, in GCN2-depleted cells.
We then studied the effects of VCP inhibition and GCN2
depletion on protein synthesis by immunoblotting for pur-
omycinylated proteins (Fig. 5c). We found that glucose or
glutamine depletion alone distinctly attenuated protein
synthesis at the 36 h time point. VCP/p97 inhibition had a
similar effect on protein synthesis, which was not enhanced
by nutrient depletion. GCN2 depletion did not have a dis-
tinct quantifiable effect on protein synthesis under any of
the stress conditions tested, although glucose depletion may
have had a slightly more pronounced effect on protein
synthesis in GCN2-depleted cells at the 36 h time point.
Thus, despite different effects of nutrient limitations and
VCP/p97 inhibition on eIF2αSer51 phosphorylation, these
metabolic stresses had a comparable effect on overall pro-
tein synthesis.
Discussion
VCP/p97 regulates multiple cellular functions by virtue of
its segregase activity [73]. Here, we provide evidence that
VCP/p97 also acts as a central regulator of cellular meta-
bolism, first by linking VCP/p97 with multiple metabolic
processes on a transcriptional level, both across a large
number of cancer cell lines and in primary tumour cells
from a sizeable cohort of patients with MM. We then went
on to uncover bidirectional functional interactions between
VCP/p97 and cellular metabolism. We observed that glu-
tamine depletion resulted in VCP/p97 upregulation both at
the mRNA and protein level, and that VCP/p97 inhibition
was linked to increased glutamine levels. The latter may be
explained at least partly by the recent finding that VCP/p97
promotes degradation of GS [37]. A mechanistic link for the
former is less apparent. However, given the central role of
VCP/p97 in the ubiquitin-proteasome system (UPS), and
considering that amino acid starvation increases not only
cellular dependency on proteasomal protein degradation but
also the synthesis of proteasome subunits [74, 75], it is not
unlikely that induction of VCP/p97 is part of a ‘UPS
response’ to starvation. In conjunction with the findings by
Van Nguyen et al. [37] that VCP/p97 link glutamine
metabolism with the immunomodulatory drug target
CRBN, our data further highlight VCP/p97 as a promising
anticancer drug target that may be particularly important in
‘glutamine-addicted’ [76] cancers.
We found that CB5083 treatment triggered significant
increases in the levels of not just glutamine but most amino
acids. Considering that proteasome inhibition decreases
intracellular amino acids [30, 75], our findings raise the
question why inhibition of VCP/p97 has the opposite effect.
One possible explanation could be that VCP/p97 inhibition
has a profound suppressive effect on de novo protein
synthesis, and thus amino acid usage. This effect could also
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result in a general decrease in the demand for carbon and
thus explain the accumulation of various metabolites that
we observed. However, considering the wide range of
cellular functions that are governed by VCP/p97, which
include amino acid-regulating processes as specific as GS-
mediated synthesis of glutamine and as general as
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autophagy, it seems likely that a complex array of effects on
protein synthesis and degradation as well as metabolism are
at play. While it is beyond the scope of this study to elu-
cidate these processes, the data presented here underpin the
biological importance of VCP/p97 in metabolism and pro-
vide the framework for further studies.
In this study, we also provide evidence for a cytopro-
tective role of GCN2. While GCN2 depletion did not have a
detectable impact on cell viability or stress signalling in
unstressed cells, we observed an incremental increase in the
cellular requirement for GCN2 when cells were challenged
with nutrient depletion, VCP/p97 inhibition, or both toge-
ther. Our data are therefore compatible with observations
that GCN2 is dispensable in mice unless they receive a low
amino acid diet or are treated with L-asparaginase [77–80].
Together with reports that GCN2 promotes cancer cell
survival and tumour angiogenesis under conditions of
nutrient deprivation [61, 62], our observations provide
further support for the notion that inhibition of GCN2 could
be of therapeutic benefit. Moreover, GCN2 inhibition might
be most effective in sensitising cancer cells in nutrient-poor
tumour areas to drugs that affect amino acid metabolism,
such as proteasome inhibitors or L-asparaginase, without
relevant toxic effects on normal tissues.
While our observations on the cytoprotective role of
GCN2 under different stress conditions are robust, it
remains unclear precisely how GCN2 protects cells. To our
surprise, we found that GCN2 depletion had limited effects
on metabolites, including amino acids. The main effects we
observed suggest that GCN2 activity attenuates depletion of
glycolytic metabolites, which may support ongoing bio-
synthetic processes. We also found that GCN2 reduced the
cellular requirement for survival-promoting ERK signalling
and autophagy in glutamine-depleted and CB5083-treated
cells. Our observations differ from previous reports that
autophagy is activated downstream of GCN2, and that ERK
mediates metabolic stress-induced cell death upstream of
GCN2 [57–59, 63, 71]. While these discrepancies may be
partly explained by differences in experimental conditions
and cell types used, they also highlight the complexities of
adaptive measure that may be triggered in cancer cells.
In summary, we uncovered a role for VCP/p97 in cancer
cell metabolism and in maintaining cancer cell ER protein
homoeostasis under nutrient-restricted conditions. We also
demonstrate that GCN2 signalling represents a mechanism
by which cancer cells can cope with the combined action of
VCP/p97 inhibition and nutrient deprivation (Fig. 6), by
attenuating stress signalling and cell death, and by mod-
ulating ERK signalling, autophagy, and glycolytic meta-
bolism. The findings are of relevance for anticancer
therapies that target mechanisms of protein and metabolic
homoeostasis. In particular, our observations highlight the
need to investigate how the proteasome, a key partner of
VCP/p97 in protein degradation, links protein and meta-
bolic homoeostasis.
Materials and methods
Cells and cell culture reagents
A549 lung adenocarcinoma cells were a gift from Jane
Mitchell (Imperial College London, London, UK). MCF-7
breast cancer cells were a gift from Dr. Ernesto Yagüe
(Imperial College London, London, UK). PC3 and DU145
prostate cancer cells were a gift from Dave Carling
(Imperial College London, London, UK). Saos-2 osteo-
sarcoma cells and A172 glioblastoma cells were obtained
from the European Collection of Authenticated Cell Cul-
tures operated by Public Health England, UK. Cell culture
identity was verified by short tandem repeat profiling pro-
vided by the University of Sheffield, UK, and the European
Collection of Authenticated Cell Cultures operated by
Public Health England, UK. A549 cells stably expressing
Fig. 5 Effects of GCN2 on metabolites and protein synthesis. a Bar
graphs show metabolite levels in shGCN2 A549 cells compared to
shNTC cells in different media (fold change for each of the
three media compositions (16 h), and metabolite levels in shGCN2(1)
cells (fold change to shNTC cells) after treatment with CB5083 (1 μM,
16 h). Comparisons with significant effects are outlined in red (n= 4,
two-way ANOVA). b, c Immunoblot analyses for the indicated pro-
teins on whole-cell extracts from A549 cells (three independent
experiments) stably expressing shNTC or shGCN2(1). Bar graphs

















Fig. 6 Proposed schematic model for the coordinated action of VCP/
p97 and GCN2 to maintain metabolic and proteostatic homoeostasis.
Under basal conditions, VCP/p97 promotes controlled protein turnover
and metabolic homoeostasis. When VCP/p97 is functionally impaired,
for example by pharmacological inhibition with CB5083, protein
synthesis and metabolic processes are diminished, resulting in the
accumulation of amino acids and metabolites. Additional nutrient
shortages aggravate the proteostatic and metabolic imbalance and
enhance cellular dependency on GCN2
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inducible control shRNA or inducible shRNA targeting
VCP/p97 (clones 4252–2 and 4252–3) were described
before and were a kind gift from Dan Anderson (Cleave
Biosciences) [29]. Cell lines were regularly tested for
mycoplasma contamination using the MycoAlert Myco-
plasma Detection Kit (Lonza, Cambridge, UK). Cells were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma-Aldrich, MO, USA) supplemented with
10% foetal bovine serum (FBS; Life Technologies, CA,
USA) and 1% penicillin plus streptomycin solution (Sigma-
Aldrich). For nutrient-depletion experiments, we used
DMEM (Life Technologies, catalogue number A14430-01)
supplemented with 2% phenol red solution (Sigma-
Aldrich), 1% penicillin plus streptomycin, and 10% dia-
lysed FBS (Gibco, Thermo Fisher, MA, USA, catalogue
number A3382001). For ‘low glucose’ medium, we added
1 mM of D-(+) glucose solution (Sigma-Aldrich, catalogue
number G844) and 2 mM L-glutamine (Sigma-Aldrich,
catalogue number G7513). For ‘no glutamine’ medium, we
added 25 mM of D-(+) glucose solution. For ‘complete’
medium, both 25 mM D-(+) glucose and 2 mM L-glutamine
were added. All cells were cultured in a humidified atmo-
sphere of 5% CO2 at 37 °C.
Antibodies for immunoblotting and other reagents
Antibodies used for immuoblotting were as follows (cata-
logue numbers): eIF2α (9722S), β-tubulin (2146S), LC3B
(2775S), PERK (5683S), p62 (5114S), ERK1/2 (137F5),
phospho-ERK1/2 (Thr202/Tyr204) (9101), anti-rabbit IgG
HRP-linked and anti-mouse IgG HRP-linked (7074S) (all
from Cell Signalling Technology, MA, USA). Phospho-
eIF2α (Ser51) (E90) (ab32157), VCP (ab11433) antibodies
were from Abcam. PageRuler Plus Prestained Protein
Ladder (Thermo Fisher) was used as a molecular weight
marker. CB5083 (Stratech Scientific), Bafilomycin A1
(Sigma-Aldrich), Chloroquine (Sigma-Aldrich), AZD6244
(VWR), U0126 (Sigma-Aldrich), z-VAD-fmk (Promega),
IPTG (VWR), and puromycin (InvivoGen) were dissolved
in dimethylsulphoxide (DMSO) and stored at −20 °C.
shRNA-mediated stable GCN2 knockdown
Stable shRNA-mediated GCN2 knockdown was achieved
using pLKO.1 cloning vector (Addgene, Cambridge, MA,
USA) with GFP replacing the puromycin insert. Briefly,
pLKO stuffer was released upon digestion with EcoRI and
AgeI (New England Biolabs, MA, USA). Oligos were
annealed and ligated into the pLKO.1, producing a final
plasmid expressing the shRNA of interest (shGCN2(1),
shGCN2(2), and non-targeting shNTC (Supplementary
Table 1)). DH5α cells (New England Biolabs) were trans-
formed with ligation mix and plated on LB agar plates
containing ampicillin. Positive clones were identified by
sequencing with a pLKO.1 sequencing primer (5′ CAA
GGC TGT TAG AGA GAT AAT TGG A 3′). Maxi prep
using GeneJet Plasmid Maxiprep Kit (ThermoFisher) was
carried out to produce large-scale quantities of the plasmid.
Lentiviral particles were generated with HEK-293T (Gen-
Hunter) to carry out the viral transfection using X-treme
Gene HP kit (Roche, Switzerland). Transfection efficiency
was confirmed after 48 h; 72 h post-transfection virus was
collected by ultracentrifugation. A549 cells were transduced
and GFP-positive cells were sorted by FACS.
Cell viability
Viable cells were quantified by flow cytometric analysis
using Dead Cell Apoptosis Kit with Annexin V Alexa
Fluor™ 488 and 7-amino-actimomycin D (7-AAD)
according to the manufacturer instruction. Cells were ana-
lysed using a BD LSRFortessa™ (BD Biosciences). Cell
viability was also assessed by RealTime-Glo™ MT Cell
Viability Assay (Promega, Madison, WI, USA) according
to the manufacturer’s instructions, using 3000 cells per well
in 96-well white opaque-walled plates and a FLUOstar
Omega microplate reader (BMG Labtech).
Caspase activity assay
A total of 20,000 cells per well were seed in 96-well white
opaque-walled plates. Following experimental treatment as
indicated, Caspase-Glo® 3/7 Assay (Promega, catalogue
number G8091) reagent was added according to the man-
ufacturer’s instructions and luminescence was read on a
Fluoroscan Ascent FL plate reader (Thermo Fisher
Scientific).
mRNA expression analysis by real-time RT-PCR
Cells were snap frozen using liquid nitrogen. RNA was
extracted using the GeneJET RNA Purification Kit (Thermo
Fisher) followed by removal of genomic DNA according to
the manufacturer’s instructions. cDNA synthesis was per-
formed using the RevertAid First Strand cDNA Synthesis
Kit (Thermo Fisher) according to the manufacturer’s
instructions using an Applied Biosystems 2720 Thermal
Cycler (Life Technologies, Carlsbad, CA, USA). PCR
reactions were performed on an Applied Biosystems Ste-
pOnePlus machine (Applied Biosystems, Foster City, CA,
USA) using 10 μl SYBR Green JumpStart Taq ready Mix
(Sigma-Aldrich), 0.3 μM sequence-specific primers (Sup-
plementary Table 1), and 25 ng cDNA under standard
conditions. Expression levels were quantified using the
ΔΔCt or standard curve method with GAPDH as the control
gene. GAPDH expression was confirmed to be stable in the
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different stress conditions tested, with minimal differences
in Ct values that were not linked to a particular experimental
condition.
Western blotting
Whole-cell protein extracts were prepared on ice using a
lysis buffer (Cell Signaling Technology) supplemented with
Complete EDTA-free Protease Inhibitor Cocktail (Roche).
After 10 min on ice and centrifugation at 4 °C, 14,000 rpm
for 10 min, the supernatant was collected. The protein
concentration was measured using a Bradford reagent (Bio-
Rad Laboratories, CA, USA) according to the manu-
facturer's instruction. The proteins were denatured at 100 °C
for 5 min with standard SDS-PAGE Loading Buffer and
separated via 6–15% SDS polyacrylamide gel electrophor-
esis and transferred to a PVDF membrane, followed by
blocking with TBS-T (0.1%) containing 5% non-fat milk
for 1 h at room temperature, incubated with specific primary
antibody at 4 °C for 16 h, and then incubated with sec-
ondary antibody labelled with horseradish peroxidase
(HRP) for 1 h at RT. Finally, an electrochemiluminescence
(ECL, GEHealthcare) system was used for detection of
specific proteins. Intensity of the bands was measured using
ImageJ software. The quantification reflects the relative
amounts as a ratio of each protein band relative to the lane’s
loading control.
Analysis of protein synthesis by puromycin labelling
Semiquantitative monitoring of protein synthesis was car-
ried out based on the previously described SUnSET method
[81]. Briefly, newly synthesised peptides were labelled in
cultured cells by the addition of puromycin (InvivoGen, San
Diego, CA, USA); 5 μg/ml for 10 min before cells were
collected and whole-cell extracts were prepared for immu-
noblotting as described above, using anti-puromycin anti-
body clone 12D10 (Merck Millipore, Darmstadt, Germany.
Bioinformatic analyses
RMA-normalised expression data were downloaded from
GEO (GSE36133, GSE15695) and the expression of VCP/
p97 was correlated with all other probes. Multi-mapping
probes were split, un-annotated probes were removed, and
the most significant probe per gene was kept for down-
stream analysis. VCP/p97 gene correlation values were used
as input to GSEA analysis against KEGG pathways using
the R package ClusterProfiler [82]. Network graphs were
produced with igraph using genes within the leading edge
subset of the three most significantly enriched KEGG
pathways [83].
Statistical analysis
Unless stated otherwise, data on mRNA or protein expres-
sion and viability show means and standard error of the
mean (SEM) from three independent experiments. Mann–
Whitney U test to compare two sample means or one-way/
two-way ANOVA with multiple comparison tests as indi-
cated in the figure and table legends were performed using
GraphPad Prism 7 software (GraphPad Software, CA,
USA).
GC-MS of intracellular metabolites
Intracellular metabolites were extracted from cultured cells
by cold methanol quenching. Aqueous metabolites were
separated from the intracellular extract using a 2:1:3
chloroform:methanol:water extraction method. The aqueous
portion of the extract was separated and lyophilised in
silanized 1.5 ml glass vials prior to analysis. Samples were
derivatized for GC–MS using a two-step methoximation–
silylation procedure. Samples were incubated with 20 μl of
20 mg/ml methoxyamine in anhydrous pyridine at 30 °C for
90 min, followed by the addition of 80 μl of N-methyl-N-
trimethylsilyltrifluoroacetamide with 1% trimethyl-
chlorosilane and incubating at 37 °C for 30 min. Samples
were analysed on an Agilent 7890 gas chromatograph
connected to an Agilent 5975 MSD using the FiehnLib
settings [84]. GC–MS data were processed by deconvolu-
tion using AMDIS using the Fiehn library, followed by
integration using GaVIN [85] based on the quantitation ion
for each metabolite as taken from the Fiehn library. Back-
ground signals determined from an extraction blank were
subtracted from the data, and were subjected to a smoothed-
spline normalisation using repeat-injected pooled QC sam-
ples. Metabolite measurements were normalised to cell
number. Statistical analyses of metabolome data were per-
formed in R (3.3.0). The effects of treatment with the p97
inhibitor and with shGCN2 were evaluated through a two-
way ANOVA for each of the three different media com-
positions separately. Effects of culture in low glucose or no
glutamine media compared to full media were evaluated
through a Student’s t-test. The calculated p-values were
adjusted for multiple comparisons [86] to control the false
discovery rate.
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